Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in ctDNA-positive stage II/III colon cancer
NCT05178576Phase 2Withdrawn
- Sponsor
- NSABP Foundation
- Start
- Jun 2022
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gevokizumab in colon cancer, sponsored by NSABP Foundation. Planned start Jun 2022; status: withdrawn.
02
Drugs
gevokizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05178576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178576.